Calendario›SNY›ARMADA-AD

ARMADA-AD

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Ensayo de Sanofi en Dermatitis atopica.

Más ensayos de: Dermatitis atópica.

Fase

no aplica

Estado

Reclutando pacientes

Participantes

1.000

previstos

Centros

82

Fin del objetivo primario

ene 2034

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en nov 2025.

Qué mide

Number of Participants Utilizing Atopic Dermatitis (AD) Treatment (Baseline to up to 60 months) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions. The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07290803), actualizada en sep 2026.